These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
51 related articles for article (PubMed ID: 6464769)
1. [Studies on polyphase liposome of camptothecin, PL-CSA]. Luo JD; Ma ZQ; Gu XQ Yao Xue Xue Bao; 1984 Jan; 19(1):63-8. PubMed ID: 6464769 [No Abstract] [Full Text] [Related]
2. [Study on preparation and tissue distribution of hydroxycamptothecin liposomes]. Zhao Z; Xie J; Liu W; Zhou J Zhongguo Zhong Yao Za Zhi; 2011 Feb; 36(4):450-4. PubMed ID: 21598539 [TBL] [Abstract][Full Text] [Related]
3. Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice. Knight V; Koshkina N; Waldrep C; Giovanella BC; Kleinerman E; Gilbert B Trans Am Clin Climatol Assoc; 2000; 111():135-45. PubMed ID: 10881338 [No Abstract] [Full Text] [Related]
4. [A method for determining the encapsulation ratio of camptothecin in polyphase liposome and studies on its leakage property]. Zhang QM; Gu XQ; Sha Y; Zhang YH Yao Xue Xue Bao; 1987 Dec; 22(12):918-22. PubMed ID: 3450136 [No Abstract] [Full Text] [Related]
5. In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin. Watanabe M; Kawano K; Toma K; Hattori Y; Maitani Y J Control Release; 2008 May; 127(3):231-8. PubMed ID: 18384903 [TBL] [Abstract][Full Text] [Related]
6. Chronic liposome administration in mice: effects on reticuloendothelial function and tissue distribution. Allen TM; Murray L; MacKeigan S; Shah M J Pharmacol Exp Ther; 1984 Apr; 229(1):267-75. PubMed ID: 6707942 [TBL] [Abstract][Full Text] [Related]
7. [Preparation of amylopectin modified dipyridamole liposome and its tissue distribution in mice]. Cheng J; Zhu JB; Yang SX; Wang CB Yao Xue Xue Bao; 2006 Mar; 41(3):277-81. PubMed ID: 16759003 [TBL] [Abstract][Full Text] [Related]
8. [The determination methods for the size and distribution of particles and particulate matter in intravenous injections of polyphase liposome (139) in the form of suspensions]. Deng YJ; Shi SF; Yu YM; Li HQ; Han GC; Gu XQ Yao Xue Xue Bao; 1987 Feb; 22(2):145-9. PubMed ID: 3618240 [No Abstract] [Full Text] [Related]
9. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts. Zamboni WC; Strychor S; Joseph E; Walsh DR; Zamboni BA; Parise RA; Tonda ME; Yu NY; Engbers C; Eiseman JL Clin Cancer Res; 2007 Dec; 13(23):7217-23. PubMed ID: 18056203 [TBL] [Abstract][Full Text] [Related]
10. [Comparative organ distribution of various sizes of liposomes during their intravenous administration]. Isanin NA; Rozenberg OA; Shcherbakov LM; Khanson KP; Davidenkova EF Vopr Med Khim; 1984; 30(1):37-41. PubMed ID: 6710935 [TBL] [Abstract][Full Text] [Related]
11. [Distribution and excretion of camptothecin suspension and sodium camptothecin in mice (author's transl)]. Chen RT; Hua Z; Lu ZX; Xu B Zhongguo Yao Li Xue Bao; 1980 Dec; 1(2):109-12. PubMed ID: 6461180 [No Abstract] [Full Text] [Related]
12. Camptothecin-catalyzed phospholipid hydrolysis in liposomes. Saetern AM; Skar M; Braaten A; Brandl M Int J Pharm; 2005 Jan; 288(1):73-80. PubMed ID: 15607259 [TBL] [Abstract][Full Text] [Related]
13. Enhancement of adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers. Gabizon A; Goren D; Fuks Z; Barenholz Y; Dagan A; Meshorer A Cancer Res; 1983 Oct; 43(10):4730-5. PubMed ID: 6883331 [TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. Emerson DL; Bendele R; Brown E; Chiang S; Desjardins JP; Dihel LC; Gill SC; Hamilton M; LeRay JD; Moon-McDermott L; Moynihan K; Richardson FC; Tomkinson B; Luzzio MJ; Baccanari D Clin Cancer Res; 2000 Jul; 6(7):2903-12. PubMed ID: 10914740 [TBL] [Abstract][Full Text] [Related]
15. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. Hattori Y; Kawakami S; Suzuki S; Yamashita F; Hashida M Biochem Biophys Res Commun; 2004 May; 317(4):992-9. PubMed ID: 15094367 [TBL] [Abstract][Full Text] [Related]
16. [The inhibitory effect of tissue plasminogen activator combined with 5-fluorouracil polyphase liposome on the scar formation in experimental filtration surgery]. Jing M; Xi S; Chen R Zhonghua Yan Ke Za Zhi; 1997 Sep; 33(5):376-80. PubMed ID: 10451987 [TBL] [Abstract][Full Text] [Related]
17. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Kong G; Braun RD; Dewhirst MW Cancer Res; 2000 Aug; 60(16):4440-5. PubMed ID: 10969790 [TBL] [Abstract][Full Text] [Related]
18. [Physical stability of intravenous injection of polyphase liposome (139) in the form of suspension]. Deng YJ; Su DS; Li HQ; Gu XQ Yao Xue Xue Bao; 1984 Apr; 19(4):282-7. PubMed ID: 6496104 [No Abstract] [Full Text] [Related]
19. Effects of liposome dose and the presence of lymphosarcoma cells on blood clearance and tissue distribution of large unilamellar liposomes in mice. Ellens H; Morselt HW; Dontje BH; Kalicharan D; Hulstaert CE; Scherphof GL Cancer Res; 1983 Jun; 43(6):2927-34. PubMed ID: 6687832 [TBL] [Abstract][Full Text] [Related]
20. [Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice]. Chen T; Hou SX; Wang YY; Zhang WS; Chen DH Yao Xue Xue Bao; 2006 Dec; 41(12):1170-5. PubMed ID: 17290615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]